NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent central radiology review. Overall survival, response rate, and clinical benefit rate were secondary endpoints. BC [4] . However, progressive disease ultimately develops in virtually all patients, either as early novo resistance) or as relapse/progression after initial response (acquired resistance) [5] .
A significant proportion of tumors in BC patients retain their sensitivity to endocrinedirected approaches even after disease progression on prior endocrine therapy, and may respond to another endocrine agent [6, 7] .
In view of the favorable safety profile of endocrine-directed agents, extending the benefit of endocrine therapy at relapse/ progression is an important clinical consideration. In particular, the low toxicity of endocrine agents compared with chemotherapy represents a major advantage in a population of patients with a high incidence of comorbidities. However, sequential lines of single-agent endocrine therapy are associated with modest clinical benefit [6, 7] . Accordingly, combination endocrine therapies [8] [9] [10] and co-targeting of downstream elements of the molecular pathways associated with BC progression and the development of endocrine resistance [e.g., histone deacetylase or mammalian target of rapamycin (mTOR)] have been investigated [11, 12] . Preclinical and clinical evidence shows that everolimus (EVE), a rapamycin derivative, has direct anticancer effects, and that mTOR inhibition can enhance the efficacy of endocrine therapy in breast tumors [13] [14] [15] . The strategy of dual inhibition with endocrine therapy and an mTOR inhibitor was investigated in the Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial [16] .
Data from the protocol-defined interim analysis at 7. 
Study Assessments
Tumor assessments were based on computed tomography (CT) scans or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis at baseline and every 6 weeks until disease progression. Patients who discontinued one or both study treatments for any reason other than progression were followed with the same assessment schedule until progression. A bone scan or skeletal survey using radiography, CT scanning, or MRI was required within 6 weeks before randomization. Abnormalities observed on bone scans were assessed using the same method every 6 weeks. After discontinuation of treatment, patients who progressed were followed every 3 months for survival. Hematologic parameters, biochemical measures, and vital signs were assessed at baseline and at each visit, and the lipid profile was assessed every 6 weeks. Adverse events (AEs)
were monitored continuously throughout the study and graded according to Common
Terminology Criteria for Adverse Events, version 3.0 [17] .
Statistical Analysis
The primary efficacy analysis of PFS by local investigator assessment required 528 PFS events to achieve 90% power to detect an HR of 0.74 (26% risk reduction) using a log-rank test and 2-look Lan-DeMets group [18] sequential design with O'Brien-Fleming-type boundary at a onesided cumulative 2.5% significance level; one interim analysis was conducted after observing 60% of events (previously reported) [16] . Based on the magnitude and stability of the EVE treatment effect over time, as well as lowerthan-expected event rates, final analysis after slightly fewer events than planned (i.e., 510 events) was considered appropriate.
RESULTS
A total of 724 patients were randomized between June 2009 and January 2011 to receive EVE?EXE (n = 485) or PBO?EXE (n = 239). Baseline characteristics were similar between treatment groups (Table 1 ) [16] . At baseline, 77% of patients had bone lesions (21% had bone-only lesions), and of the approximately 59% with visceral disease, 84% had involvement at 2 or more sites. In the EVE?EXE arm, median duration of exposure to EVE was 23.9 weeks (range 1.0-123.3 weeks) and median exposure to EXE was 29.5 weeks (range 1.0-123.3 weeks). In the PBO?EXE arm, median exposure to EXE was 14.07 weeks (range 1.0-101.0 weeks). The (Fig. 1b) . The effect of EVE?EXE treatment (assessed by local investigators) was consistent across patient subgroups defined by patient characteristics and prior therapy, with an estimated HR ranging between 0.25 and 0.62 (Fig. 2a) .
These analyses were concordant with similar subgroup analyses from data based on central review (Fig. 2b) [13] .
Enhanced response in the neoadjuvant setting has also been reported with the combination of EVE with NSAI letrozole versus letrozole alone [14] .
The principal treatment goal for HR ? advanced BC is disease control. In this context, the benefit of prolonging PFS is clinically relevant provided patient QOL is maintained. Analysis of patient-reported outcomes from BOLERO-2 demonstrated that, despite the higher incidence of AEs with EVE?EXE versus EXE alone, QOL was maintained [20] . These rates are slightly higher than the rates reported at the interim analysis [16] , presumably because of increased drug exposure with longer follow-up. This suggests that the significantly improved clinical efficacy outcomes achieved by adding EVE to EXE may have outweighed the impact of toxicity [20] .
Current guidelines recommend sequential administration of another line of endocrine therapy at relapse/progression after previous endocrine therapy, whereas chemotherapy is recommended for patients requiring rapid symptom control or who have exhausted three prior lines of endocrine treatment [2, 4] .
Although endocrine therapy has a favorable toxicity profile, second-or third-line endocrinedirected approach has so far demonstrated modest efficacy, with CBR ranging from 25% to 35% [6, 8] . Randomized controlled comparisons of experimental single [6, 7] or combination endocrine agents [8, 10] showed minimal to no improvement in median PFS or time to progression versus EXE (3.7 months post-NSAI) [6] or fulvestrant (from 4.4 months post-NSAI to 6.5 months post-AI/antiestrogen) [7] . In contrast, the BOLERO-2 study data demonstrate that EVE?EXE significantly improved median PFS by more than twofold versus EXE alone.
Current guidelines also acknowledge that cytotoxic chemotherapy regimens (whether single agents or combinations) are generally effective in controlling rapidly progressing disease, but are associated with considerable toxicity [8, 21] . Moreover, the clinical benefits from sequential chemotherapy in patients previously exposed to cytotoxic agents in the adjuvant and/or metastatic setting may be limited because of treatment resistance, as well as the potential risk of cumulative toxicities such as cardiac, gastrointestinal, hematologic, and neurologic toxicities [21] . Given the palliative intent of treatment in the second or higher line of therapy and the toxicities associated with chemotherapy, postponing the initiation of cytotoxic therapy can be an important consideration for patients and physicians [22] . In this respect it is important to note that all patient subsets [including those with disease characteristics that might support the use of chemotherapy (e.g., visceral metastases and/or multiple metastatic sites)] in the BOLERO-2 study experienced clinical benefit similar to that of the overall population treated with EVE?EXE.
The AE profile of EVE?EXE in this analysis from BOLERO-2 after 18-month median followup is consistent with the established safety profile of EVE in other settings [23, 24] . Notably, these updated analyses show no substantial risk of cumulative toxicities or new safety signals despite a 60% increase in cumulative treatment exposure in the EVE?EXE arm. Adverse events of clinical interest associated with EVE treatment included stomatitis, rash, noninfectious pneumonitis, infections, and metabolic abnormalities, with the majority being grade 1/2. The majority of these events were effectively resolved using protocol-defined management strategies based on extensive prior experience and resulting clinical recommendations for the management of EVErelated AEs in medical oncology (e.g., renal cell carcinoma) [25] [26] [27] . Overall, vigilance and proactive monitoring for signs and symptoms of key AEs are key to facilitate prolonged treatment with EVE [26] .
CONCLUSION
The BOLERO-2 trial is the first phase 3 study to demonstrate that dual blockade of the endocrine and mTOR pathways is a feasible and adequately tolerated strategy that provides significant clinical benefit. The final analysis of the primary endpoint from the BOLERO-2 study demonstrates that EVE?EXE is well tolerated and provides clinically meaningful PFS benefit versus EXE alone in the overall population of patients with HR
? advanced BC progressing during/after NSAI therapy, irrespective of age, and among clinically relevant subsets of patients including those receiving first-line treatment for advanced disease, and patients with visceral involvement. Overall, these data support the use of combination therapy with EVE?EXE to substantially improve PFS without compromising QOL, thereby achieving an important goal in the management of advanced BC.
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